Abstract:Adverse drug events, encompassing both adverse drug reactions and medication errors, pose a significant threat to health, leading to illness and, in severe cases, death. Timely and voluntary reporting of adverse drug events by healthcare professionals plays a crucial role in mitigating the morbidity and mortality linked to unexpected reactions and improper medication usage. To assess the effectiveness of different interventions aimed at healthcare professionals to improve the reporting of adverse drug events. We searched CENTRAL, Embase, MEDLINE and several other electronic databases and trials registers, including ClinicalTrials.gov and WHO ICTRP, from inception until 14 October 2022. We also screened reference lists in the included studies and relevant systematic reviews. We included randomised trials, non‐randomised controlled studies, controlled before‐after studies, interrupted time series studies (ITS) and repeated measures studies, assessing the effect of any intervention aimed at healthcare professionals and designed to increase adverse drug event reporting. Eligible comparators were healthcare professionals' usual reporting practice or a different intervention or interventions designed to improve adverse drug event reporting rate. We excluded studies of interventions targeted at adverse event reporting following immunisation. Our primary outcome measures were the total number of adverse drug event reports (including both adverse drug reaction reports and medication error reports) and the number of false adverse drug event reports (encompassing both adverse drug reaction reports and medication error reports) submitted by healthcare professionals. Secondary outcomes were the number of serious, high‐causality, unexpected or previously unknown, and new drug‐related adverse drug event reports submitted by healthcare professionals. We used GRADE to assess the certainty of evidence. We followed standard methods recommended by Cochrane and the Cochrane Effective Practice and Organisation of Care (EPOC) Group. We extracted and reanalysed ITS study data and imputed treatment effect estimates (including standard errors or confidence intervals) for the randomised studies. We included 15 studies (eight RCTs, six ITS, and one non‐randomised cross‐over study) with approximately 62,389 participants. All studies were conducted in high‐income countries in large tertiary care hospitals. There was a high risk of performance bias in the controlled studies due to the nature of the interventions. None of the ITS studies had a control arm, so we could not be sure of the detected effects being independent of other changes. None of the studies reported on the number of false adverse drug event reports submitted. There is low‐certainty evidence suggesting that an education session, together with reminder card and adverse drug reaction (ADR) report form, may substantially improve the rate of ADR reporting by healthcare professionals when compared to usual practice (i.e. spontaneous reporting with or without some training provided by regional pharmacosurveillance units). These educational interventions increased the number of ADR reports in total (RR 3.00, 95% CI 1.53 to 5.90; 5 studies, 21,655 participants), serious ADR reports (RR 3.30, 95% CI 1.51 to 7.21; 5 studies, 21,655 participants), high‐causality ADR reports (RR 2.48, 95% CI 1.11 to 5.57; 5 studies, 21,655 participants), unexpected ADR reports (RR 4.72, 95% CI 1.75 to 12.76; 4 studies, 15,085 participants) and new drug‐related ADR reports (RR 8.68, 95% CI 3.40 to 22.13; 2 studies, 7884 participants). Additionally, low‐certainty evidence suggests that, compared to usual practice (i.e. spontaneous reporting), making it easier to report ADRs by using a standardised discharge form with added ADR items may slightly improve the total number of ADR reports submitted (RR 2.06, 95% CI 1.11 to 3.83; 1 study, 5967 participants). The discharge form tested was based on the 'Diagnosis Related Groups' (DRG) system for recording patient diagnoses, and the medical and surgical procedures received during their hospital stay. Due to very low‐certainty evidence, we do not know if the following interventions have any effect on the total number of adverse drug event reports (including both ADR and ME reports) submitted by healthcare professionals: ‐ sending informational letters or emails to GPs and nurses; ‐ multifaceted interventions, including financial and non‐financial incentives, fines, education and reminder cards; ‐ implementing government regulations together with financial incentives; ‐ including ADR report forms in quarterly bulletins and prescription pads; ‐ providing a hyperlink to the reporting form in hospitals' electronic patient records; ‐ improving the reporting method by re‐engineering a web‐based electronic error reporting system; ‐ the presence of a clinical pharmacist in a hospital setting actively identify -Abstract Truncated-

An analysis of international strategies for monitoring and preventability described in medicinal product information: a study protocol

Interventions that help to improve spontaneous adverse drug reaction reporting by patients: a protocol of a scoping review

Methods for drug safety signal detection using routinely collected observational electronic health care data: a systematic review

Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines

An evaluation of statistical approaches to postmarketing surveillance

Methods of detection of adverse events in critical care: a protocol for a systematic review

Assessing the knowledge and practice of the Irish Community Pharmacists in reporting Adverse Drug Reactions and Falsified Medicines

Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance

Developing a process to measure actual harm from medication errors in paediatric inpatients: From design to implementation

Detection and prevention of medication misadventures in general practice

Statistical Signal Detection Algorithm in Safety Data: A Proprietary Method Compared to Industry Standard Methods

Serious adverse events reporting in recent randomised clinical trials in intensive care medicine – A methodological study protocol

Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-method study

The state of the art in secondary pharmacology and its impact on the safety of new medicines

The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process

Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof-of-Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action

Improving adverse drug event reporting by healthcare professionals

Web-Based Signal Detection Using Medical Forums Data in France: Comparative Analysis

Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023

Optimising computerised decision support to transform medication safety and reduce prescriber burden: study protocol for a mixed-methods evaluation of drug–drug interaction alerts

The Value of Social Media Analysis for Adverse Events Detection and Pharmacovigilance: Scoping Review